<DOC>
	<DOCNO>NCT03086200</DOCNO>
	<brief_summary>CCTG 603 open-label , two-arm , randomize ( 1:1 ) clinical demonstration project determine brief Motivational Interviewing ( MI-B ) add text-message base adherence intervention ( iTAB ) improve adherence PrEP among transgender person .</brief_summary>
	<brief_title>CCTG 603 : Randomized Controlled Trial iTAB Plus Motivational Interviewing PrEP Adherence Transgender Individuals ( The iM-PrEPT Study )</brief_title>
	<detailed_description>A total 300 HIV-uninfected transgender gender non-conforming individual , define currently identify gender different sex assign birth , high-risk transmission behavior enrol study . Each participant follow maximum 48 week enrollment . The primary endpoint measure 48 week , last week study participant discontinue early . All participant start PrEP TDF / FTC fix dose combination take daily . Subjects randomize ( 1:1 ) iTAB text message adherence reminder intervention either without brief motivational interviewing ( MI-b ) suboptimal adherence . All participant receive iTAB system provide personalize , automate text message support monitor adherence . In MI-b arm , poor adheres iTAB report receive target MI-b via telephone . Both group receive PrEP accordance standardize comprehensive method prescribe , include risk reduction counseling , adherence counseling , clinical assessment safety monitoring , well HIV STI screening .</detailed_description>
	<criteria>Transgender identity , define identify gender different assign birth Age 18 year old Subjects must substantial ongoing risk acquisition HIV evident one following : Has least one HIV infect sexual partner â‰¥4 week OR , Had male transgender female partner past 12 month AND least one following : 1. condomless anal vaginal sex past 12 month 2. STI diagnose report past 12 month 3. exchange money , gift , shelter , drug sex 4. anticipated unprotected anal vaginal sex male transgender female partner next month Negative HIV infection nucleic acid test ( NAT ) sensitive method 4th generation antigen/antibody test Acceptable renal function measure calculated creatinine clearance least 60 mL/min CockcroftGault formula ( eCcr ( male ) mL/min = [ ( 140 age year ) x ( lean body weight kg ) ] / ( 72 x serum creatinine mg/dL ) past 30 day Unable give inform consent Active hepatitis B define positive hepatitis B surface antigen ( HBsAg ) Substantial medical condition , opinion investigator , would preclude participation , define gastrointestinal condition would impair absorption study drug know condition reduce bone density ( e.g . osteoporosis osteogenesis imperfect ) significantly elevate risk bone fracture neurological severe psychiatric condition would significantly impair ability adhere PrEP tubular glomerular kidney disease could exacerbate tenofovir medical condition would unacceptably increase risk harm study drug significantly impair ability adhere PrEP Suspected sensitivity allergy study drug component Currently use essential product medication interacts study drug following : antiretroviral agent ( include nucleoside analogs , nonnucleoside reverse transcriptase inhibitor , integrase inhibitor , protease inhibitor investigational antiretroviral agent ) currently TDF/FTC PEP PrEP switch study provide drug continue antiretroviral agent agent know nephrotoxic potential : aminoglycoside antibiotic ( include gentamicin ) IV amphotericin B cidofovir cisplatin foscarnet IV pentamidine IV vancomycin oral IV gancyclovir agent significant nephrotoxic potential drug slow renal excretion probenecid immune system modulators systemic chemotherapeutic agent ( i.e . cancer treatment medication ) ongoing systemic corticosteroid ( exception short course taper steroid dos asthma self limited condition ) . interleukin2 ( IL2 ) interferon ( alpha , beta , gamma ) agent know significant interaction TDF FTC Proteinuria 2+ great urine dipstick Pregnancy ( individual uterus ) Other condition , opinion investigator , would put participant risk , complicate interpretation study outcome data , would otherwise interfere participation achieve study objective</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PrEP</keyword>
	<keyword>Pre-exposure Prophylaxis</keyword>
	<keyword>Text messaging</keyword>
	<keyword>Truvada</keyword>
	<keyword>Motivational interviewing</keyword>
	<keyword>Transgender</keyword>
	<keyword>Gender Non-conforming</keyword>
</DOC>